P411 - ASSOCIATION BETWEEN BLOOD SELENIUM INCREASE AND MORTALITY IN BURN PATIENTS RECEIVING SELENIUM SUPPLEMENTATION: A RETROSPECTIVE COHORT STUDY

P411

ASSOCIATION BETWEEN BLOOD SELENIUM INCREASE AND MORTALITY IN BURN PATIENTS RECEIVING SELENIUM SUPPLEMENTATION: A RETROSPECTIVE COHORT STUDY

J. Park^1,*

¹Burn surgery, Hallym university Hangang Sacred Heart Hospital, Seoul, Korea, Republic Of

Rationale: Selenium has antioxidant and immunomodulatory effects and is often used as adjunctive therapy in burn care. Despite this, the clinical impact of actual changes in selenium levels is unclear. We investigated the relationship between changes in blood selenium and mortality in burn ICU patients treated with selenium between 2022 and 2025.

Methods: This retrospective cohort study included burn ICU patients who received selenium supplementation. Patients were classified based on whether their blood selenium increased or decreased during treatment. Multivariable logistic regression was used to evaluate the association between selenium changes and mortality, adjusting for TBSA, age, and inhalation injury.

Results: Of 154 treated patients, 110 (71.4%) showed increased selenium, and 44 (28.6%) did not. Mortality was significantly lower in the increased group (9.1%) versus the decreased group (39%, p<0.001). Selenium increase was independently associated with lower mortality (OR 0.144, 95% CI 0.046–0.409, p<0.001). TBSA and age were positively associated with mortality (OR per 1% TBSA: 1.08, 95% CI 1.04–1.12, p<0.001; OR per year of age: 1.08, 95% CI 1.03–1.13, p=0.002). Inhalation injury showed a non-significant trend toward higher mortality (p=0.080).

Conclusion: These findings suggest that in burn patients receiving selenium supplementation, an actual increase in blood selenium levels is significantly associated with reduced mortality. The therapeutic response to selenium may depend not just on the dose administered but on the patient’s capacity to achieve increased circulating selenium levels. Further prospective studies are needed to clarify mechanisms and optimize supplementation protocols.

Disclosure of Interest: None declared